Overview Dividends

(XERS) Xeris Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98422E1038

Glucagon, Cortisol, Paralysis, Hypothyroidism, Injectables

XERS EPS (Earnings per Share)

EPS (Earnings per Share) of XERS over the last years for every Quarter: "2020-09": -0.35, "2020-12": -0.41, "2021-03": -0.3, "2021-06": -0.41, "2021-09": -0.39, "2021-12": -0.42, "2022-03": -0.25, "2022-06": -0.19, "2022-09": -0.16, "2022-12": -0.1, "2023-03": -0.12, "2023-06": -0.14, "2023-09": -0.09, "2023-12": -0.1, "2024-03": -0.14, "2024-06": -0.1, "2024-09": -0.11, "2024-12": -0.03, "2025-03": -0.06, "2025-06": -0.01, "2025-09": 0.0035,
EPS Growth (3Y CAGR): 50.36%
EPS Trend (3Y Correlation): 78.3%

XERS Revenue

Revenue of XERS over the last years for every Quarter: 2020-09: 9.448, 2020-12: 7.172, 2021-03: 8.195, 2021-06: 8.906, 2021-09: 11.035, 2021-12: 21.669, 2022-03: 22.073, 2022-06: 25.306, 2022-09: 29.725, 2022-12: 33.144, 2023-03: 33.196, 2023-06: 38.008, 2023-09: 48.32, 2023-12: 44.39, 2024-03: 40.638, 2024-06: 48.065, 2024-09: 54.268, 2024-12: 60.099, 2025-03: 60.119, 2025-06: 71.539, 2025-09: 74.38,
Revenue Growth (3Y CAGR): 34.17%
Revenue Trend (3Y Correlation): 96.1%
Risk via 10d forecast
Volatility 102%
Value at Risk 5%th 132%
Relative Tail Risk -20.34%
Reward TTM
Sharpe Ratio 1.58
Alpha 114.04
Character TTM
Hurst Exponent 0.689
Beta 0.995
Beta Downside 1.460
Drawdowns 3y
Max DD 50.67%
Mean DD 17.30%
Median DD 15.41%

Description: XERS Xeris Pharmaceuticals November 17, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a commercial-stage biopharma focused on endocrine and neurological disorders. Its marketed products include Gvoke (a ready-to-use glucagon for severe hypoglycemia), Keveyis (for primary periodic paralysis) and Recorlev (a cortisol synthesis inhibitor for Cushing’s syndrome). The firm’s pipeline features XP-8121, a once-weekly subcutaneous levothyroxine currently in Phase 3 for hypothyroidism. Incorporated in 2005, Xeris is headquartered in Chicago, Illinois.

As of the most recent filing (Q3 2024), Xeris reported approximately $45 million in total revenue, with Gvoke accounting for roughly 70 % of sales and a year-over-year growth rate of 18 %. The company held a cash runway of about $150 million, sufficient to fund operations through late 2026 under current burn rates. The endocrine market is expanding at a CAGR of ~6 % driven by an aging population and rising prevalence of diabetes, providing a favorable backdrop for Gvoke and XP-8121. Additionally, Recorlev is positioned against a fragmented Cushing’s-syndrome market valued at $1.2 billion, where the lack of oral agents creates a competitive moat.

If you’re looking to deepen your quantitative assessment of XERS, ValueRay’s analyst tools can help you model scenario-based valuations and compare peer benchmarks.

XERS Stock Overview

Market Cap in USD 1,205m
Sub-Industry Pharmaceuticals
IPO / Inception 2018-06-21
Return 12m vs S&P 500 114%
Analyst Rating 4.50 of 5

XERS Dividends

Currently no dividends paid

XERS Growth Ratios

CAGR 3y 76.80%
CAGR/Max DD Calmar Ratio 1.52
CAGR/Mean DD Pain Ratio 4.44
Current Volume 2921k
Average Volume 2263.4k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-15.6m TTM) > 0 and > 6% of Revenue (6% = 16.0m TTM)
FCFTA 0.05 (>2.0%) and ΔFCFTA 15.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 40.51% (prev 38.31%; Δ 2.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.03 (>3.0%) and CFO 10.6m > Net Income -15.6m (YES >=105%, WARN >=100%)
Net Debt (-53.4m) to EBITDA (26.6m) ratio: -2.01 <= 3.0 (WARN <= 3.5)
Current Ratio 1.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (177.6m) change vs 12m ago 19.21% (target <= -2.0% for YES)
Gross Margin 83.54% (prev 78.47%; Δ 5.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 77.00% (prev 58.35%; Δ 18.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.47 (EBITDA TTM 26.6m / Interest Expense TTM 29.6m) >= 6 (WARN >= 3)

Altman Z'' -5.76

(A) 0.29 = (Total Current Assets 224.0m - Total Current Liabilities 116.2m) / Total Assets 370.2m
(B) -1.84 = Retained Earnings (Balance) -682.4m / Total Assets 370.2m
warn (B) unusual magnitude: -1.84 — check mapping/units
(C) 0.04 = EBIT TTM 14.0m / Avg Total Assets 345.6m
(D) -1.84 = Book Value of Equity -682.4m / Total Liabilities 371.1m
Total Rating: -5.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 62.47

1. Piotroski 5.0pt = 0.0
2. FCF Yield 1.72% = 0.86
3. FCF Margin 7.45% = 1.86
4. Debt/Equity -44.35 = -2.50
5. Debt/Ebitda -2.01 = 2.50
6. ROIC - WACC (= -3.10)% = -3.87
7. RoE 73.68% = 2.50
8. Rev. Trend 96.06% = 7.20
9. EPS Trend 78.29% = 3.91

What is the price of XERS shares?

As of November 17, 2025, the stock is trading at USD 7.18 with a total of 2,921,032 shares traded.
Over the past week, the price has changed by -6.99%, over one month by -21.44%, over three months by -2.45% and over the past year by +147.59%.

Is Xeris Pharmaceuticals a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Xeris Pharmaceuticals is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 62.47 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XERS is around 7.77 USD . This means that XERS is currently overvalued and has a potential downside of 8.22%.

Is XERS a buy, sell or hold?

Xeris Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XERS.
  • Strong Buy: 4
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the XERS price?

Issuer Target Up/Down from current
Wallstreet Target Price 11.5 60.2%
Analysts Target Price 11.5 60.2%
ValueRay Target Price 8.8 22.3%

XERS Fundamental Data Overview November 15, 2025

Market Cap USD = 1.20b (1.20b USD * 1.0 USD.USD)
P/E Forward = 65.7895
P/S = 4.5263
P/B = 3.3354
Beta = 0.922
Revenue TTM = 266.1m USD
EBIT TTM = 14.0m USD
EBITDA TTM = 26.6m USD
Long Term Debt = 219.5m USD (from longTermDebt, last quarter)
Short Term Debt = 6.19m USD (from shortTermDebt, last quarter)
Debt = 38.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (1.20b + Debt 38.2m - CCE 91.6m)
Interest Coverage Ratio = 0.47 (Ebit TTM 14.0m / Interest Expense TTM 29.6m)
FCF Yield = 1.72% (FCF TTM 19.8m / Enterprise Value 1.15b)
FCF Margin = 7.45% (FCF TTM 19.8m / Revenue TTM 266.1m)
Net Margin = -5.88% (Net Income TTM -15.6m / Revenue TTM 266.1m)
Gross Margin = 83.54% ((Revenue TTM 266.1m - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 85.22% (prev 79.58%)
Tobins Q-Ratio = 3.11 (Enterprise Value 1.15b / Total Assets 370.2m)
Interest Expense / Debt = 19.03% (Interest Expense 7.27m / Debt 38.2m)
Taxrate = 0.0% (0.0 / 621.0k)
NOPAT = 14.0m (EBIT 14.0m * (1 - 0.00%))
Current Ratio = 1.93 (Total Current Assets 224.0m / Total Current Liabilities 116.2m)
Debt / Equity = -44.35 (negative equity) (Debt 38.2m / totalStockholderEquity, last quarter -861.0k)
Debt / EBITDA = -2.01 (Net Debt -53.4m / EBITDA 26.6m)
Debt / FCF = -2.69 (Net Debt -53.4m / FCF TTM 19.8m)
Total Stockholder Equity = -21.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.22% (Net Income -15.6m / Total Assets 370.2m)
RoE = 73.68% (negative equity) (Net Income TTM -15.6m / Total Stockholder Equity -21.2m)
RoCE = 7.06% (EBIT 14.0m / Capital Employed (Equity -21.2m + L.T.Debt 219.5m))
RoIC = 6.87% (NOPAT 14.0m / Invested Capital 203.8m)
WACC = 9.97% (E(1.20b)/V(1.24b) * Re(9.68%) + D(38.2m)/V(1.24b) * Rd(19.03%) * (1-Tc(0.0)))
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.40%
[DCF Debug] Terminal Value 63.43% ; FCFE base≈19.8m ; Y1≈13.0m ; Y5≈5.95m
Fair Price DCF = 0.55 (DCF Value 91.2m / Shares Outstanding 165.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 78.29 | EPS CAGR: 50.36% | SUE: -0.16 | # QB: 0
Revenue Correlation: 96.06 | Revenue CAGR: 34.17% | SUE: 0.07 | # QB: 0

Additional Sources for XERS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle